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Aims: The aim of this study was to describe the risks of cardiovascular (CV) events and severe
hypoglycaemia with insulin degludec (degludec) vs insulin glargine 100 units/mL (glargine U100)
in patients with type 2 diabetes (T2D) aged 65 years or older.
Materials and methods: A total of 7637 patients in the DEVOTE trial, a treat-to-target, random-
ized, double-blind trial evaluating the CV safety of degludec vs glargine U100, were divided into
three age groups (50-64 years, n = 3682; 65-74 years, n = 3136; ≥75 years, n = 819). Out-
comes by overall age group and randomized treatment differences were analysed for major
adverse cardiovascular events (MACE), all-cause mortality, severe hypoglycaemia and serious
adverse events (SAEs).
Results: Patients with increasing age had higher risks of CV death, all-cause mortality and SAEs,
and there were non-significant trends towards higher risks of MACE and severe hypoglycaemia.
Treatment effects on the risk of MACE, all-cause mortality, severe hypoglycaemia and SAEs
were consistent across age groups, based on the non-significant interactions between treatment
and age with regard to these outcomes.
Conclusions: There were higher risks of CV death, all-cause mortality and SAEs, and trends
towards higher risks of MACE and severe hypoglycaemia with increasing age after adjusting for
baseline differences. The effects across age groups of degludec vs glargine U100 on MACE, all-
cause mortality and severe hypoglycaemia were comparable, suggesting that the risk of MACE,
as well as all-cause mortality, is similar and the risk of severe hypoglycaemia is lower with
degludec regardless of age. Evidence is conclusive only until 74 years of age.
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The global burden of type 2 diabetes (T2D) in patients aged 65 years
or older is projected to increase substantially during the next few
decades, as patients with diabetes live longer and the incidence of dia-
betes continues to rise.1 Thus, the growing problem of diabetes and
its consequences in patients aged 65 years or older is an important
public health concern.
The management of diabetes in patients aged 65 years or older
presents unique challenges. Differences in drug metabolism as the
result of deteriorating kidney and liver function and the challenges of
polypharmacy related to the treatment of multiple co-morbidities lead
to a higher risk of drug-drug interactions and adverse events in this
population.2,3 Cardiovascular disease (CVD), in particular, is a common
complication and co-morbidity among many older individuals with dia-
betes is the leading cause of mortality in this population.4 Further
complicating treatment, patients aged 65 years or older are more sus-
ceptible to severe hypoglycaemic events than younger patients, in
part because of a reduced ability to recognize and respond to symp-
toms.5,6 Severe hypoglycaemia has been shown to be associated with
a higher risk of adverse cardiovascular (CV) events and mortality.7,8 In
addition, severe hypoglycaemic episodes can increase utilization of
healthcare resources.9 Several organizations have published guidelines
for managing T2D in patients aged 65 years or older; however, most
of these are based on expert opinion only, as there is a lack of high-
quality evidence from randomized clinical trials in this population.10–13
Although most guidelines support the use of insulin as one of several
treatment options, data suggest that it is under-utilized in patients
aged 65 years or older,14 and there are few long-term studies in this
population that demonstrate the efficacy and safety of basal
insulins.15–17 Possible reasons for under-utilization of insulin in this
population include lack of clinical evidence, less stringent glycaemic
targets suggested in recent recommendations, and the potential ele-
vated risk of and concern about hypoglycaemia in these
individuals.5,11–14,17
CV safety and the lower risk of severe hypoglycaemia with insulin
degludec (degludec) compared with insulin glargine 100 units/mL
(glargine U100) was demonstrated in a double-blind trial in patients
with T2D who were at high risk of CV events (DEVOTE).16,18 Given
the mean age (65 years) of the study population,16 DEVOTE provides
a unique opportunity to investigate CV safety and the risk of severe
hypoglycaemia with degludec vs glargine U100 in patients with T2D
aged 65 years or older who are at high risk of CV events.
2 | METHODS
2.1 | DEVOTE trial overview
DEVOTE was a multicentre, treat-to-target, randomized, double-blind,
active-comparator trial that evaluated the CV safety of degludec vs
glargine U100, in addition to standard of care, in patients with T2D
who were at high risk of CV events. This trial was designed to con-
tinue until the occurrence of at least 633 MACEs, as confirmed by a
central, blinded event adjudication committee (EAC).16,18
The detailed trial design, trial protocol and primary results have been
published previously.16,18
DEVOTE (ClinicalTrials.gov NCT01959529) was conducted in
accordance with the Declaration of Helsinki and ICH Good Clinical
Practice Guideline.19,20 The protocol was approved by independent
ethics committees or institutional review boards for each centre. Writ-
ten informed consent was obtained from each participant.
Patients were considered for the trial if they had been diagnosed
with T2D and were undergoing treatment with at least one antihyper-
glycaemic agent, if they had an HbA1c value of at least 7.0%
(53 mmol/mol) or were undergoing treatment with at least
20 units/day of basal insulin. Criteria for eligibility for the trial were:
at least 50 years of age with a history of prior CVD or moderate
chronic kidney disease (CKD); or were at least 60 years of age with
one or more pre-specified CV risk factors.16
Primary adjudicated outcome was the time from randomization to
first occurrence of a three-component MACE: CV death, non-fatal
myocardial infarction (MI) or non-fatal stroke. Secondary confirmatory
outcome was the number of EAC-confirmed events of severe
hypoglycaemia, defined according to American Diabetes Association
guidelines as an episode requiring assistance of another person to
actively administer carbohydrate or glucagon, or to take other correc-
tive actions.8
2.2 | Statistical analysis
In these secondary analyses, all randomized patients (n = 7637, full
analysis set [FAS]) were categorized into three age groups: 50 to
64 years (n = 3682), 65 to 74 years (n = 3136) and ≥75 years
(n = 819). These age groups and statistical analyses of all endpoints
were pre-specified, with the exception of analyses of serious adverse
events (SAEs). Comparisons across age groups, treatment differences
within each age group, and interaction between treatment and age
groups were investigated for all endpoints. Analyses were based on
FAS and followed previous analyses of the DEVOTE data,16 with the
exception of adjustment for the following pre-specified baseline vari-
ables: sex, region, diabetes duration, CV risk, insulin-naïve, smoking
status and kidney function. It was of particular importance to adjust
for baseline CV risk, as patients between 50 and less than 60 years of
age were required to have established CVD in order to be included in
the trial, whereas those 60 years of age or older could have either CV
risk factors or established CVD.
As details of the analyses have been described previously,7,16
only a brief summary is provided here. Time-to-first event were
analysed using Cox proportional hazard regression models. The
numbers of severe and nocturnal severe (00:01 AM-05:59 AM, both
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inclusive) hypoglycaemic events and SAEs were analysed using a
negative binomial-regression model. Associations between severe
hypoglycaemia and subsequent accidents and injuries (within one
day, defined according to standardized Medical Dictionary for Regu-
latory Activities query), time to first MACE and time to all-cause
mortality (any time after a severe hypoglycaemic event) were
analysed using a Cox regression model with treatment and previous
severe hypoglycaemia (Yes/No) as time-varying covariates, and were
adjusted for the baseline covariates listed above, similar to those in
DEVOTE 3.7
Interactions with age group, pooled across treatments for insulin
dose (U/kg), HbA1c and fasting plasma glucose (FPG), were analysed
using a mixed model for repeated measures (MMRM) within patients
using an unstructured residual covariance matrix among visits.
P values were not multiplicity adjusted and a P value less than 0.05
was considered significant.
3 | RESULTS
3.1 | Baseline characteristics
The lowest proportion of patients with established CVD/CKD, com-
pared with the other age groups (50-64 years or ≥75 years) was in
the 65 to 74 years age group (Table 1), in part the result of the inclu-
sion criteria. Compared with the 50 to 64 years age group, the 65 to
74 and ≥75 years age groups had a longer duration of diabetes and
had lower body weight, body mass index (BMI), pulse, HbA1c, FPG,
estimated glomerular filtration rate (eGFR), total cholesterol and tri-
glycerides, and a lower proportion of patients in these groups were
identified as smokers. Differences in the above baseline characteris-
tics and demographic variables between age groups were significant
(all P < 0.001).
3.2 | Cardiovascular and mortality outcomes
There was a trend towards higher risks of MACE and non-fatal stroke
across the age groups and a significantly higher risk of CV death in the
≥75 years age group, as compared with the 50 to 64 years age group
(Figure 1). Compared with the 50 to 64 years and the 65 to 74 years
age groups, the risk of all-cause mortality was significantly higher in
the ≥75 years age group (Figure 1). There was no evidence of hetero-
geneity of the effects of degludec vs glargine U100 on MACE, on all-
cause mortality (Figures 2 and S1) or on individual MACE components
(CV death, non-fatal MI and non-fatal stroke) (Figures 2 and S2)
among age groups (Figure 2).
3.3 | Severe and nocturnal severe hypoglycaemia
The risks of severe and nocturnal severe hypoglycaemia in patients
aged ≥75 years, compared with those aged 50 to 64 and 65 to
74 years (Figure 1) were numerically higher. There was a lower risk of
severe hypoglycaemia with degludec vs glargine U100 across age
groups, although a non-significant trend was demonstrated in patients
aged ≥75 years (Figures 2 and S3). This lower risk with degludec vs
glargine U100 was also observed for nocturnal severe hypoglycaemia
in patients aged 50 to 64 and 65 to 74 years but was not evident in
the 16 events observed among patients aged ≥75 years (Figure 2).
There was no evidence of interaction between randomized treatment
and age group for severe or nocturnal severe hypoglycaemia
(Figure 2).
3.4 | Association between severe hypoglycaemia
and time to first MACE and time to all-cause mortality
by age group
The risk of MACE after a severe hypoglycaemic event in the two older
age groups was higher compared with before an event; this was signif-
icant in the 65 to 74 years age group (hazard ratio [HR], 1.69; 95% CI,
1.03-2.77) and not significant in the ≥75 years age group (HR, 1.58;
95% CI, 0.71-3.51) (Figure S4). Concerning time to all-cause mortality,
there was a significantly higher risk following a severe hypoglycaemic
event in all age groups (≥75 years: HR, 2.20; 95% CI, 1.11-4.33;
65-74 years: HR, 2.36; 95% CI, 1.42-3.92; 50-64 years: HR, 1.95;
95% CI, 1.01-3.75) (Figure S4).
3.5 | Glycaemic control
Both total and basal insulin dose (U/kg) were significantly lower in the
two older age groups after 24 months of treatment, compared with
the younger age group (Figures S5 and S6A). However, there was no
evidence of an association between randomized treatment and age
group for total, basal and bolus insulin doses (P interaction = 0.63,
0.41 and 0.38, respectively) (Figure S6B).
Concerning change in HbA1c from baseline to Month 24, there was
no significant difference between age groups, with the exception of the
65 to 74 years age group, which had a significantly greater reduction in
HbA1c compared with the 50 to 64 years age group (Figure S7). Similarly,
concerning change in FPG from baseline to Month 24, there was no sig-
nificant difference across age groups; degludec achieved a significantly
greater reduction in FPG during the same period compared with glargine
U100 in all age groups (Figure S8). There was no evidence of an associa-
tion between randomized treatment and age group for HbA1c and FPG
(HbA1c: P interaction = 0.62; FPG: P interaction = 0.58).
Across the three age groups, there were no significant differences
in day-to-day fasting self-measured blood glucose (SMBG) variability
(pooled treatments). In addition, there was a consistently lower day-
to-day fasting SMBG variability with degludec compared with glargine
U100 across age groups [P < 0.05].
3.6 | Serious adverse events
The most frequent SAEs were cardiac disorders, which occurred in
15.0% of patients aged 50 to 64 years, in 15.5% of patients aged 65 to
74 years and in 19.0% of patients aged ≥75 years of age (Table S1).
The oldest age group (≥75 years) had significantly higher rates of SAEs
compared with the 50 to 64 years and 65 to 74 years age groups
(Figure 1). The proportion of patients in the ≥75 years age group who
had accidents and injuries was 6.2% (rate, 4.19/100 patient-years of
observation [PYO]), whereas, in the 50 to 64 years and 65 to 74 years
age groups, the proportions were 3.7% (rate, 2.29/100 PYO) and 3.5%
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TABLE 1 Baseline characteristics by age groups
Characteristic
50-64 years 65-74 years ≥75 years
n = 3682 n = 3136 n = 819
Age (years) 58.9 ± 4.0 68.8 ± 2.8 78.2 ± 3.1
Male 2273 (61.7) 2008 (64.0) 497 (60.7)
Ethnicity
Hispanic or Latino 591 (16.1) 438 (14.0) 108 (13.2)
Race
White 2596 (70.5) 2510 (80.0) 669 (81.7)
Asian 452 (12.3) 283 (9.0) 41 (5.0)
Black 500 (13.6) 253 (8.1) 79 (9.6)
Other 134 (3.5) 90 (2.8) 30 (3.7)
Established CVD/CKD 3169 (86.1) 2620 (83.5) 720 (87.9)
Smoker (yes) 557 (15.1) 262 (8.4) 33 (4.0)
Diabetes duration (years) 14.5 ± 7.9 17.8 ± 9.1 19.8 ± 10.2
Body weight (kg) 97.9 ± 24.0 95.5 ± 22.2 90.4 ± 19.0
BMI (kg/m2) 34.1 ± 7.2 33.4 ± 6.6 32.1 ± 5.8
Blood pressure
Systolic (mmHg) 135.1 ± 18.0 135.9 ± 18.1 136.0 ± 17.8
Diastolic (mmHg) 78.6 ± 10.0 74.4 ± 10.1 72.1 ± 10.2
Heart rate (beats/min) 74.8 ± 11.2 71.8 ± 11.3 70.4 ± 10.9
HbA1c (%) 8.7 ± 1.8 8.2 ± 1.5 8.0 ± 1.4
[mmol/mol] [71.8 ± 19.6] [66.0 ± 16.1] [64.1 ± 14.7]
FPG (mmol/L) 10.0 ± 4.2 9.1 ± 3.6 8.9 ± 3.5
[mg/dL] [180.7 ± 76.2] [164.2 ± 63.9] [159.5 ± 62.2]
eGFR (mL/min/1.73m2) based on CKD-EPI 74.9 ± 21.9 63.2 ± 19.2 54.9 ± 16.9
Total cholesterol (mmol/L) [mg/dL] 4.4 ± 1.3 [170.8 ± 50.0] 4.2 ± 1.2 [160.5 ± 44.2] 4.1 ± 1.1 [157.1 ± 40.7]
LDL-C (mmol/L) [mg/dL] 2.3 ± 1.0 [89.4 ± 38.5] 2.1 ± 0.9 [82.3 ± 34.5] 2.1 ± 0.8 [79.5 ± 32.4]
HDL-C (mmol/L) [mg/dL] 1.1 ± 0.3 [43.8 ± 12.7] 1.2 ± 0.3 [44.6 ± 12.9] 1.2 ± 0.3 [46.5 ± 13.3]
Triglycerides (mmol/L) [mg/dL] 2.3 ± 2.2 [200.7 ± 191.0] 2.0 ± 1.4 [173.2 ± 126.7] 1.8 ± 1.2 [160.0 ± 106.9]
Antihyperglycaemic medication at baseline
Insulins
Long acting 2101 (57.1) 1973 (62.9) 523 (63.9)
Intermediate actinga 602 (16.3) 384 (12.2) 88 (10.7)
Short acting 1281 (34.8) 1244 (39.7) 306 (37.4)
Premix 413 (11.2) 294 (9.4) 75 (9.2)
Other antihyperglycaemic treatment (excluding insulins)
Metformin 2406 (65.3) 1800 (57.4) 358 (43.7)
Sulfonylurea 1050 (28.5) 921 (29.4) 258 (31.5)
Alpha glucosidase inhibitor 73 (2.0) 49 (1.6) 11 (1.3)
Thiazolidinedione 112 (3.0) 128 (4.1) 28 (3.4)
DPP-4i 438 (11.9) 379 (12.1) 126 (15.4)
GLP-1RA 292 (7.9) 271 (8.6) 41 (5.0)
SGLT-2i 83 (2.3) 67 (2.1) 18 (2.2)
Others 34 (0.9) 58 (1.8) 26 (3.2)
CV medication at baseline
Antihypertensive therapy 3389 (92.0) 2948 (94.0) 772 (94.3)
Diuretics 1753 (47.6) 1630 (52.0) 433 (52.9)
Lipid-lowering drugs 2961 (80.4) 2623 (83.6) 690 (84.2)
Platelet aggregation inhibitors 2631 (71.5) 2267 (72.3) 592 (72.3)
Anti-thrombotic medication 185 (5.0) 296 (9.4) 116 (14.2)
Note. Full analysis set; data listed are number (proportion [%]) for discrete variables and mean ± SD for continuous variables.
Abbreviations: BMI, body mass index; CKD, chronic kidney disease; CV, cardiovascular; CVD, cardiovascular disease; DPP-4i, dipeptidyl peptidase-4 inhibi-
tors; eGFR, estimated glomerular filtration rate; EPI, epidemiology collaboration formula; FPG, fasting plasma glucose; GLP-1RA, glucagon-like peptide-1
receptor agonist; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NPH, neutral protamine Hagedorn; SGLT-2i,
sodium-glucose co-transporter-2 inhibitor.
aIntermediate-acting insulins include human insulins, neutral protamine Hagedorn and unknown types of insulins.
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(rate, 2.53/100 PYO), respectively. Furthermore, there was a signifi-
cantly higher risk of accidents and injuries following, within one day, a
severe hypoglycaemic event, regardless of age (229 times higher risk in
the 50 to 64 years age group [P < 0.0001], 60 times higher risk in the
65 to 74 years age group [P < 0.0001] and 619 times higher risk in the
≥75 years age group [P < 0.0001]). However, there were no significant
differences between treatments in the risk of accidents and injuries.
There were trends towards a lower risk of SAEs with degludec in the
65 to 74 years and ≥75 years age groups, and a significantly lower risk
of SAEs in the 50 to 64 years age group as compared with glargine
U100 (Figure 2). In addition, similar to what was observed with primary
outcomes, concerning SAEs, there were no significant interactions
between randomized treatment and age group (Figure 2).
4 | DISCUSSION
Results from these secondary analyses demonstrated that there was a
trend towards higher risks of MACE and severe hypoglycaemia, and
significantly higher risks of CV death, all-cause mortality and SAEs
with increasing age. There was no evidence for heterogeneity of the
effects of degludec vs glargine U100 with regard to the risk of MACE,
all-cause mortality and SAEs at similar levels of glycaemic control in
patients with T2D who are aged 65 years or older compared with
younger patients. The results suggest that the CV safety and lower
severe hypoglycaemia of degludec versus glargine U100 in patients
with T2D observed in the overall results of the DEVOTE trial16 were
similar for participants below or above 65 years of age. However,
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FIGURE 1 Age group comparisons concerning time to first MACE and its components (CV death, non-fatal MI and non-fatal stroke), time to all-
cause mortality, number of severe and nocturnal severe hypoglycaemic events and SAEs (pooled treatments; adjusted for baseline covariates). All
comparisons accounted for age group, treatment, interactions between age group and treatment, sex, region, diabetes duration, CV risk, insulin-
naïve status, smoking status and kidney function at baseline. Severe hypoglycaemia was defined, according to the American Diabetes Association,
as an episode requiring the assistance of another person to actively administer carbohydrate or glucagon, or to take other corrective actions.8
Nocturnal severe hypoglycaemia was defined as an episode with an investigator-reported onset between 00:01 AM and 5:59 AM. Abbreviations:
CI, confidence interval; CV, cardiovascular; MACE, major adverse cardiovascular event; MI, myocardial infarction; SAE, serious adverse event
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while there was strong evidence for treatment effects until the age of
74 years, there was no conclusive evidence for the group of patients
who were 75 years or older, as reflected by the wide confidence
intervals.
At baseline, there was a higher proportion of patients 75 years or
older with established CVD/CKD, as compared with the 65 to 74 years
age group, an observation that was not surprising given that these
are common T2D-related complications in patients 65 years or older.1
Favours degludec Favours glargine U100
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1.21 [0.80; 1.84] 46 12.2 42 10.0
0.88 [0.70; 1.12] 135 8.6 145 9.6
0.84 [0.67; 1.06] 137 7.6 162 8.9
Time to CV death 0.27
0.98 [0.55; 1.73] 22 5.9 25 5.9
1.16 [0.81; 1.66] 67 4.3 55 3.7
0.75 [0.51; 1.11] 45 2.5 60 3.3
Time to first non-fatal MI 0.13
1.45 [0.74; 2.83] 20 5.3 15 3.6
0.67 [0.46; 0.96] 49 3.1 70 4.6
0.86 [0.63; 1.19] 70 3.9 81 4.5
Time to first non-fatal stroke 0.77
1.20 [0.49; 2.95] 10 2.7 9 2.1
0.83 [0.50; 1.37] 29 1.9 33 2.2
0.85 [0.52; 1.39] 30 1.7 35 1.9
Time to all-cause mortality 0.53
0.78 [0.51; 1.18] 38 10.1 54 12.8
1.03 [0.77; 1.37] 94 6.0 87 5.8
0.87 [0.63; 1.21] 68 3.8 78 4.3
Rate ratio
[95% CI]
E R E R
Number of severe hypoglycaemic events 0.65
0.76 [0.39; 1.49] 38 3.13 58 4.12
0.65 [0.45; 0.93] 114 2.28 181 3.53
0.55 [0.39; 0.77] 113 2.11 211 3.84
Number of nocturnal severe hypoglycaemic events 0.15
1.35 [0.37; 4.84] 9 0.61 7 0.45
0.51 [0.25; 1.03] 17 0.29 36 0.57
0.33 [0.17; 0.63] 18 0.27 62 0.82
Number of SAEs 0.67
0.93 [0.72; 1.20] 440 35.66 502 38.42
0.91 [0.80; 1.04] 1460 29.86 1552 32.78
0.84 [0.74; 0.96] 1382 28.40 1624 33.65
FIGURE 2 Treatment group comparisons (degludec vs glargine U100) concerning time to first MACE and its components (CV death, non-fatal MI
and non-fatal stroke), time to all-cause mortality, number of severe and nocturnal severe hypoglycaemic events and SAEs adjusted for baseline
covariates. All comparisons accounted for age group, treatment, interactions between age group and treatment, sex, region, diabetes duration, CV
risk, insulin-naïve status, smoking status and kidney function at baseline. Severe hypoglycaemia was defined, according to the American Diabetes
Association, as an episode requiring the assistance of another person to actively administer carbohydrate or glucagon, or to take other corrective
actions.8 Nocturnal severe hypoglycaemia was defined as an episode with an investigator-reported onset between 00:01 AM and 5:59 AM.
Abbreviations: %, proportion of patients experiencing events; CI, confidence interval; CV, cardiovascular; E, number of events; glargine U100,
insulin glargine 100 units/mL; MACE, major adverse cardiovascular event; MI, myocardial infarction; N, number of patients experiencing
events; R, number of events per 100 patient-years of observation; SAE, serious adverse event
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The higher proportion of patients with established CVD/CKD in the
50 to 64 years age group as compared to the 65 to 74 years age group
probably resulted from the pre-specified inclusion criterion that
required CVD/CKD in those between 50 and less than 60 years of age.
The ≥75 years age group was also characterized by a longer duration of
T2D, although not to the same degree as the difference in age. To mini-
mize the effect of differences between baseline characteristics and
demographic variables, the statistical analyses in this study were
adjusted for a number of baseline covariates. However, as age is proba-
bly still confounded by other baseline variables, the results can provide
guidance on treatment decisions, but cannot determine the effect of
age on outcomes in individuals.
The Trial Evaluating Cardiovascular Outcomes with Sitagliptin
(TECOS) demonstrated that patients with increasing age had signifi-
cantly higher risks of MACE, all-cause mortality, severe hypoglycaemia
and bone fractures,21 while pre-specified subgroup analyses of the
Action to Control Cardiovascular Risk in Diabetes (ACCORD) study
demonstrated that increased age was significantly associated with a
higher risk of hypoglycaemia that required medical assistance.22 A simi-
lar trend was observed in our study; however, there was a lack of a sig-
nificant association between MACE, severe hypoglycaemia and age.
While there was a numerically greater risk of severe hypoglycaemia
with increasing age groups (RR, 1.24 for ≥75 years vs 50-64 years and
RR, 1.26 for ≥75 years vs 65-74 years), the trend was not statistically
significant. This may be explained by the markedly smaller sample size
of the oldest age group compared with the other two age groups, lead-
ing to a higher degree of imprecision in estimates of outcomes. Further-
more, the magnitude of the association may have been influenced by
under-reporting of severe hypoglycaemia in patients living alone.
In the present study, there were higher risks of MACE, all-cause
mortality and accidents/injuries following compared with before a
severe hypoglycaemic event in patients aged 65 years or older; this
was the case especially in the ≥75 years age group, in which there
was a 619 times higher risk of accidents/injuries following a severe
hypoglycaemic event. This observation is consistent with a post hoc
analysis of data from the Veterans Affairs Diabetes Trial (VADT)
(mean age, 60.5 years), in which severe hypoglycaemia within the pre-
vious three months was significantly associated with higher risks of
serious CV events, CV death and total mortality.23 Given this evidence
and the vulnerability of this patient population to severe
hypoglycaemia,24,25 it is particularly important to minimize the occur-
rence of severe hypoglycaemia.26
The reduced risk of severe hypoglycaemia with degludec vs
glargine U100 (24%−45% reduction across the age groups) was consis-
tent with that revealed by a secondary analysis of the SWITCH 2 trial
population stratified by age (37% reduction in patients >65 years and
48% reduction in patients ≤65 years with degludec compared with
glargine U100 during the maintenance period; not significant).27 A sepa-
rate pre-planned meta-analysis of seven trials in patients with T2D
≥65 years demonstrated that degludec was associated with a significant
reduction (27% for overall hypoglycaemia and 39% for nocturnal
hypoglycaemia) in hypoglycaemic events during the maintenance
period, compared with glargine U100.28 This clinical benefit possibly
derives from the improved pharmacokinetic/pharmacodynamic profile
of degludec,29 characterized by reduced day-to-day fasting SMBG
variability with degludec compared with glargine U100 across age
groups, as observed in the present study and also supported by the
finding of a strong association between variability and severe
hypoglycaemia in all three pooled age groups. This property may allow
patients with diabetes, of all ages and all disease stages, to aim for lower
glycaemic targets without increasing their risk of hypoglycaemia.30,31 In
addition, the flexibility in dosing time with degludec32 may be beneficial
in this older population that may require assistance and may not be able
to administer insulin at regular daily intervals.
This study has a number of strengths, including the double-blind,
active-control design, the high level of CV risk of the population, and
the prospective capture and independent adjudication of CV events,
mortality and severe hypoglycaemic events. The prospective design
and multicentre, international nature of this trial and the high level of
patient follow-up further contributed to the generalizability and
robustness of the analyses. In addition, this secondary analysis was
pre-specified, with the exception of statistical analyses of the SAEs.
Although the DEVOTE trial was not powered to investigate confirma-
tory outcomes in the three age groups separately, as the only random-
ized, double-blind cardiovascular outcome clinical trial directly
comparing two basal insulins in such large numbers, it still provides
valuable information concerning these important endpoints in a popu-
lation aged 65 years or older. Nevertheless, the smaller sample size
leads to a higher degree of imprecision in results concerning the
≥75 years age group. Finally, there was no correction for multiplicity
of comparisons in these analyses.
In conclusion, there were higher risks of CV death, all-cause mor-
tality and SAEs, as well as a trend towards higher risks of MACE and
severe hypoglycaemia, with increasing age in patients with T2D. The
effects across age groups of degludec vs glargine U100 on MACE, all-
cause mortality and severe hypoglycaemia were consistent with those
of the overall DEVOTE population, suggesting that, regardless of age,
the risk of MACE and death in patients with T2D who are at high risk
of CV are comparable, and the risk of severe hypoglycaemia is lower
with degludec compared with glargine U100.
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